Bio Plus Co

Bio Plus Co EBIT per Share

The EBIT per Share of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is 243.83 KRW. In the previous year, EBIT per Share was 420.37 KRW — a change of -42.00% (lower).

EBIT per Share

243.83KRW

YoY

-42.00%

Last updated:

EBIT per Share of Bio Plus Co is 2025 243.83 KRW. EBIT per Share of Bio Plus Co was 2024 420.37 KRW. It decreases by -42.00% lower compared to the previous year.

The Bio Plus Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2020
221.55 KRW
Jan 1, 2021
297.29 KRW
Jan 1, 2022
435.75 KRW
Jan 1, 2023
490.22 KRW
Jan 1, 2024
420.37 KRW
Jan 1, 2025
243.83 KRW
Jan 1, 2026 (e)
861.37 KRW
Jan 1, 2027 (e)
926.95 KRW
The Bio Plus Co EBIT per Share history
YEAREBIT per ShareYoY
est926.95KRW+7.61%
est861.37KRW+253.27%
243.83KRW-42.00%
420.37KRW-14.25%
490.22KRW+12.50%
435.75KRW+46.57%
297.29KRW+34.19%
221.55KRW+81.26%
122.23KRW+71.15%
71.42KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

EBIT per Share of Bio Plus Co is 243.83 KRW in 2025.

EBIT per Share of Bio Plus Co changed from 420.37 KRW to 243.83 KRW, representing a -42.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Bio Plus Co

All Key Metrics — Bio Plus Co